Humacyte, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HUMA research report →
Companywww.humacyte.com
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).
- CEO
- Laura E. Niklason
- IPO
- 2020
- Employees
- 218
- HQ
- Durham, NC, US
Price Chart
Valuation
- Market Cap
- $155.80M
- P/E
- -1.88
- P/S
- 77.28
- P/B
- 15.78
- EV/EBITDA
- -1.55
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -748.51%
- Op Margin
- -5649.21%
- Net Margin
- -4840.82%
- ROE
- -2781.56%
- ROIC
- -117.66%
Growth & Income
- Revenue
- $2.04M · 0.00%
- Net Income
- $-40,833,000 · 72.54%
- EPS
- $-0.26 · 79.37%
- Op Income
- $-107,437,000
- FCF YoY
- -6.25%
Performance & Tape
- 52W High
- $2.93
- 52W Low
- $0.55
- 50D MA
- $0.84
- 200D MA
- $1.26
- Beta
- 2.31
- Avg Volume
- 7.01M
Get TickerSpark's AI analysis on HUMA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 26, 21 | FRESENIUS MEDICAL CARE HOLDINGS INC /NY/ | other | 0 |
| Nov 16, 25 | Sander Dale A. | other | 311,100 |
| Nov 16, 25 | Parikh Shamik J | other | 311,100 |
| Nov 16, 25 | Dougan Brady W | other | 311,100 |
| Nov 16, 25 | Niklason Laura E | other | 311,100 |
| Aug 18, 25 | Dougan Brady W | sell | 549,360 |
| Aug 19, 25 | Dougan Brady W | sell | 1,100,000 |
| Aug 20, 25 | Dougan Brady W | sell | 591,685 |
| Aug 18, 25 | Niklason Laura E | sell | 549,360 |
| Aug 19, 25 | Niklason Laura E | sell | 1,100,000 |
Our HUMA Coverage
We haven't published any research on HUMA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HUMA Report →